Trial intelligence / Profile preview

FAG-3 carboplatin study in women aged 70 years or older with advanced ovarian cancer

2006-005504-13Phase 2Completed

Sponsor: Hospices Civils de Lyon
Start: Dec 2006
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of carboplatin in ovarian cancer, sponsored by Hospices Civils de Lyon. Primary endpoints: Overall survival and Prognostic role of emotional distress on overall survival. Started Dec 2006; status: completed.

Drugs

carboplatin

Conditions

ovarian cancer

Beyond the preview

Go deeper on 2006-005504-13.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-005504-13.